“‘GLP Agonists’ Tag”,2023-06-01

Bibliography for tag longevity/glp, most recent first: 3 related tags, 22 annotations, & 13 links (parent).

• See Also
• Links
  • “The Benefits of GLP-1 Drugs beyond Obesity”, Drucker2024
  • “Drug Release Profile of a Novel Exenatide Long-Term Drug Delivery System (OKV-119) Administered to Cats”, Klotsman et al 2024
  • “Functional and Multi-Omic Aging Rejuvenation With GLP-1R Agonism”, Huang et al 2024
  • “Trial of Lixisenatide in Early Parkinson’s Disease”, Meissner et al 2024
  • “Is Target-Based Drug Discovery Efficient? Discovery and ‘Off-Target’ Mechanisms of All Drugs”, Sadri2023
  • “Efficacy and Safety of Oral Orforglipron in Patients With Type 2 Diabetes: a Multicenter, Randomized, Dose-Response, Phase 2 Study”, Frias et al 2023b
  • “Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists”, Alhiary et al 2023
  • “Evaluation of Out-Of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes & Cardiovascular Disease”, Luo et al 2023
  • “Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead”, Baig et al 2023
  • “The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients”, Huang et al 2023
  • “The Gut-Bone Axis in Diabetes”, Maagensen et al 2022
  • “Safety and Efficacy Assessment of a GLP-1 Mimetic: Insulin Glargine Combination for Treatment of Feline Diabetes Mellitus”, Scuderi et al 2018
  • “Targeting the GIPR for Obesity: To Agonize or Antagonize? Potential Mechanisms”, Campbell2012
  • “The GLP-1 Mimetic Exenatide Potentiates Insulin Secretion in Healthy Cats”, Gilor et al 2011
  • “Normalization of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide 1 (7-36 Amide) in Type 2 (non-Insulin-Dependent) Diabetic Patients”, Nauck et al 1993
  • “Effect of Truncated Glucagon-Like Peptide-1 [Proglucagon-(78-107) Amide] on Endocrine Secretion from Pig Pancreas, Antrum, and Nonantral Stomach”, Ørskov et al 1988
  • “GLP-1 Receptor Agonists’ Impact on Cardio-Renal Outcomes and Mortality in T2D With Acute Kidney Disease”
  • “Could Danuglipron Be the Next Ozempic in Pill Form?”
  • “GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity”
  • “Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes”
  • “Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats”
  • “Doctors Test the Limits of What Obesity Drugs Can Fix”
  • Wikipedia
• Miscellaneous
• Bibliography